Mounjaro and Kidney Function: What We Know and What to Discuss with Your Doctor

Does Mounjaro damage the kidneys?

The short answer, based on available evidence, is no, not directly. Tirzepatide was studied across the SURMOUNT clinical programme in thousands of adults with obesity, and kidney function markers were monitored as part of safety tracking. No signal of direct kidney toxicity emerged. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants taking tirzepatide at the highest doses did not show deteriorating kidney function compared with placebo. Beyond weight loss itself, there is separate evidence from semaglutide trials suggesting GLP-1-based medicines may have a kidney-protective effect in people with diabetic kidney disease, and our Mounjaro and kidneys page covers what the current evidence does and does not yet confirm for tirzepatide specifically.

What matters practically is the indirect picture. Tirzepatide slows gastric emptying and commonly causes nausea, particularly early in treatment. If that nausea becomes significant vomiting or diarrhoea, fluid loss can follow quickly, and reduced fluid intake means the kidneys are working harder to concentrate urine. Persistent dehydration is the main kidney-related concern in real-world use. The NHS tirzepatide medicines page flags dehydration and signs of kidney problems (reduced urination, dark urine, dizziness) as reasons to seek urgent medical attention.

If you find it genuinely difficult to keep fluids up on treatment, that is a clinical conversation worth having sooner rather than later. Our page on staying hydrated on Mounjaro covers practical approaches, but a persistent problem should go to your prescriber.

What happens if you already have kidney disease, can you still use Mounjaro?

This is where the answer becomes more cautious. People with mild kidney impairment (CKD stage 1 or 2, eGFR above 60) were generally included in the SURMOUNT trials, and the data do not indicate a problem at those levels. People with moderate or severe CKD, or those on dialysis, were largely excluded, which means the evidence base for those groups is thin. The licensed prescribing information does not list CKD as an absolute contraindication, but it does indicate that tirzepatide should be used with caution in renal impairment, partly because worsening dehydration from GI effects carries a higher baseline risk when kidney function is already reduced.

If you have a recorded diagnosis of CKD, a kidney transplant, or a nephrologist involved in your care, the prescriber completing your Mounjaro assessment needs to know. That information changes the risk calculation. It may mean tirzepatide is still appropriate with monitoring, or your specialist may prefer a different approach. No clinician can make that call from a keyword search. For a thorough overview of how tirzepatide intersects with kidney conditions, our Mounjaro and kidney disease page covers the clinical detail in depth.

One practical note: if you are timing a prescription around a busy period (a bank holiday, a week away) factor in that your first pen's GI effects can be unpredictable, and travel or disruption makes hydration harder. Worth planning for.

What are the warning signs that something is wrong with kidney function on Mounjaro?

The NHS lists several symptoms that warrant prompt medical attention during GLP-1 treatment, specifically relating to kidney strain from dehydration: producing noticeably less urine than usual, urine that is very dark, swelling in the ankles or feet, persistent dizziness, or feeling confused or unusually weak. Severe, persistent vomiting that prevents you keeping any fluids down is itself a reason to call 111 or see a GP that day, not to wait until your next scheduled check-in.

Kidney pain is a separate and occasionally reported concern. Flank pain during Mounjaro use can have several causes, including kidney stones, which have been reported anecdotally in people on GLP-1 medicines, though whether the medicine is a direct cause remains unclear. Our page on kidney pain and Mounjaro addresses that specific question, and if you want to understand the stone-formation angle, the Mounjaro and kidney stones page goes further. For a related look at the same topic with tirzepatide's generic name, see our coverage of tirzepatide and kidney stones.

Yellow Card reports for any unexpected symptom (including anything affecting the kidneys) can be submitted at yellowcard.mhra.gov.uk. The MHRA uses those reports to track patterns in real-world use.

How does the clinical review at nume account for kidney health?

Every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, not an automated triage system. Your health history, including any kidney conditions, medications that interact with renal function, and hydration-related risk factors, forms part of that review. People taking medicines whose levels are sensitive to kidney function (certain antibiotics, diuretics, some blood pressure drugs) may need their prescriber to review those alongside tirzepatide, because dehydration can alter drug clearance even when kidney disease itself is absent.

Transfer patients and those moving up in dose go through a fresh review each time, how we work explains that no repeat is issued without a clinical re-check. If your kidney function has changed, or you have had a recent blood test showing altered eGFR, share that information at consultation. It is exactly the kind of detail that shapes a safe prescribing decision. If you are ready to discuss your situation with our prescribers, you can start your free consultation and the team will take it from there.